Atherosclerosis Market Research Report Information By Stages (Endothelial Damage and Immune Response, Fatty Streak, Plaque Growth, and Plaque Rupture), By Diagnosis (Ankle-brachial Index (ABI), Doppler Ultrasound, Echocardiogram, Electrocardiogram (ECG), Blood Tests, and Others), By Treatment (Medication and Surgery), By End-User (Hospitals, Specialty Clinics, Homecare, and Others), By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2032

Global Atherosclerosis Market Overview

Atherosclerosis Market Size was valued at USD 45.8 Billion in 2022. The atherosclerosis market industry is projected to grow from USD 47.40 Billion in 2023 to USD 62.420 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 3.50% during the forecast period (2023 - 2032). The rising incidence of cardiovascular illnesses and atherosclerosis is the main market driver boosting the market's expansion.

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Atherosclerosis Market Trends

• 
  

  Growing incidence of of obesity is driving the market growth

  
  

Growing rates of obesity and high cholesterol are anticipated to accelerate market expansion by raising the risk of atherosclerosis. The World Health Organization estimates that 40 million children under the age of five were overweight or obese in 2018. WHO). Rapid market expansion is a result of high cholesterol rates, which are caused by increased intake of high-fat, high-sugar diets, increased physical immobility from changing modes of transportation, and increased urbanization. Additionally, it is anticipated that the market for atherosclerosis will grow because to an increase in awareness-raising campaigns by both public and private entities. Furthermore, it is anticipated that the market for atherosclerosis would grow as a result of people's sedentary lifestyles, which include excessive alcohol use and smoking addiction. Throughout the projection period, the industry's growth rate is anticipated to be driven by the high prevalence of high blood pressure and rising levels of disposable income.

With an aging population and an increasing prevalence of heart attacks due to atherosclerosis or coronary heart disease, the Atherosclerosis Market is expected to develop. Additionally, one of the main factors propelling the global market for atherosclerosis therapeutics is the accessibility of novel treatment modalities, both branded and generic. Nearly one out of every four fatalities in the United States, or about 610 000 people, was attributed to heart disease, according to the Centers for Disease Control and Prevention (CDC). The most prevalent kind of heart disease, coronary artery disease, is responsible for over 370,000 fatalities annually. It is anticipated that these reasons will increase the atherosclerosis market globally.

Patients who have atherosclerosis are more likely to suffer from heart attacks, strokes, or coronary artery disease, all of which can be fatal. Cardiovascular diseases are becoming more common, and the deaths that result from them rank among the leading causes of death worldwide. Government spending on healthcare is rising in order to improve treatment through the use of newer technology, medication therapies, apparatus, medical devices, and other infrastructure. Additionally, they are enticing private sector participants to fund the development of drugs to treat atherosclerosis by providing an advantageous business environment in their own nations. As a result, the rising cost of healthcare and advantageous laws will present profitable growth prospects for the worldwide atherosclerosis industry. Thus, driving the atherosclerosis market revenue.

Atherosclerosis Market Segment Insights:

Atherosclerosis Stage Insights

The Atherosclerosis Market segmentation, based on stage includes Endothelial Damage and Immune Response, Fatty Streak, Plaque Growth, and Plaque Rupture. The Endothelial Damage and Immune Response segment dominated the market driven by elements like the growing incidence of risk factors like diabetes and hypertension, improvements in diagnostic tools, and growing public awareness of the importance of cardiovascular health. The growth of this market segment is further aided by research & development in targeted treatments for endothelial dysfunction.

Atherosclerosis Diagnosis Insights

The Atherosclerosis Market segmentation, based on diagnosis, includes Ankle-brachial Index (ABI), Doppler Ultrasound, Echocardiogram, Electrocardiogram (ECG), Blood Tests, and Others. The Electrocardiogram (ECG) category generated the most income because to heightened awareness, improvements in ECG technology, and an increase in the incidence of atherosclerotic diseases. The aging population and the addition of ECG to telemedicine are two further factors driving the market's expansion.

Atherosclerosis Treatment Insights

The Atherosclerosis Market segmentation, based on treatment, includes Medication and Surgery. The Surgery category generated the most income ascribed to improvements in minimally invasive surgery, a rise in atherosclerosis prevalence, and growing patient awareness. The need for better treatments, aging populations, and technical advancements are some of the other factors driving the growth of the surgical market.

Figure 1: Atherosclerosis Market, by Treatment, 2022 & 2032 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Atherosclerosis End-User Insights

The Atherosclerosis Market segmentation, based on end-user, includes Hospitals, Specialty Clinics, Homecare, and Others. The hospitals category generated the most income attributed to factors including the rising prevalence of atherosclerosis, advancements in the identification and treatment of the disease, increased public awareness, and an aging population that causes a rise in the number of patients requiring hospital care.

Atherosclerosis Regional Insights

By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North American atherosclerosis market area will dominate this market The high frequency of cardiovascular illnesses and atherosclerosis, the existence of major players, and the well-established healthcare system are some of the primary causes of the market's substantial share. Moreover, favorable government programs and a rise in research partnerships are anticipated to propel market expansion.

Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2: ATHEROSCLEROSIS MARKET SHARE BY REGION 2022 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe atherosclerosis market accounts for the second-largest market share. Its substantial market share can be attributed to a number of factors, including the existence of major players, the high incidence of atherosclerosis and cardiovascular illnesses, and a developed healthcare infrastructure. Further, the German atherosclerosis market held the largest market share, and the UK atherosclerosis market was the fastest growing market in the European region

The Asia-Pacific Atherosclerosis Market is expected to grow at the fastest CAGR from 2023 to 2032 because of the region's growing percentage of elderly people and rising levels of disposable money. Additionally, the growth rate of the market in this area is anticipated to pick up speed due to the development of healthcare infrastructure and growing government initiatives. Moreover, China’s atherosclerosis market held the largest market share, and the Indian atherosclerosis market was the fastest growing market in the Asia-Pacific region.

Atherosclerosis Key Market Players & Competitive Insights

Leading market players are investing heavily in research and development in order to expand their product lines, which will help the atherosclerosis market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their global footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, atherosclerosis industry must offer cost-effective items.

Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the global atherosclerosis industry to benefit clients and increase the market sector. In recent years, the atherosclerosis industry has offered some of the most significant advantages to medicine. Major players in the atherosclerosis market are attempting to increase market demand by investing in research and development operations includes F. Hoffmann-La Roche Ltd. (Switzerland), Teva Pharmaceutical Industries Ltd. (Ireland), Sanofi (France), Allergan (Ireland), AstraZeneca (U.K.), Boehringer Ingelheim International GmbH. (Germany), Novartis AG (Switzerland), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Hikma Pharmaceuticals PLC (U.K.), Bayer AG (Germany), and Dr. Reddy's Laboratories Ltd. (India).

Teva Pharmaceutical Industries Ltd (Teva) is a company that finds, develops, produces, and sells specialty and generic medications. The company offers specialist medications for the treatment of various medical illnesses, including women's health, dermatological, cancer, respiratory, and central nervous system (CNS) disorders. It provides generic medications in many dosage forms, such as tablets, ointments, inhalants, creams, capsules, liquids, injectables, and injectables. In addition to active pharmaceutical ingredients (APIs), Teva offers over-the-counter (OTC) drugs.

Pharmaceutical business Boehringer Ingelheim International GmbH (Boehringer), a division of CH Boehringer Sohn AG & Co KG, is involved in the development, production, and distribution of medications, vaccines, parasiticides, and treatments for unmet medical needs. It provides a broad range of goods, such as biopharmaceuticals, items for animal health care, and diseases affecting humans. The company treats diseases of the central nervous system, the heart and blood vessels, the respiratory system, cancer, the immune system, and the retina, among other conditions.

Key Companies in the atherosclerosis market include

• Hoffmann-La Roche Ltd. (Switzerland)


• Teva Pharmaceutical Industries Ltd. (Ireland)


• Sanofi (France)


• Allergan (Ireland)


• AstraZeneca (U.K.)


• Boehringer Ingelheim International GmbH. (Germany)


• Novartis AG (Switzerland)


• Pfizer Inc. (U.S.)


• GlaxoSmithKline plc (U.K.)


• Hikma Pharmaceuticals PLC (U.K.)


• Bayer AG (Germany)


• Reddy's Laboratories Ltd. (India)

Atherosclerosis Industry Developments

December 2021:Vesper Medical Inc. is a US-based medical technology firm that creates minimally invasive peripheral vascular devices. Royal Philips stated that it has inked a deal to purchase the company. With a sophisticated venous stent portfolio for the treatment of deep vein illness, Vesper Medical will further broaden Philips' line of diagnostic and therapeutic devices.

Atherosclerosis Market Segmentation:

Atherosclerosis Stage Outlook

• Endothelial Damage and Immune Response


• Fatty Streak


• Plaque Growth


• Plaque Rupture

Atherosclerosis Diagnosis Outlook

• Ankle-brachial Index (ABI)


• Doppler Ultrasound


• Echocardiogram


• Electrocardiogram (ECG)


• Blood Tests


• Others

Atherosclerosis Treatment Outlook

• Medication


• Surgery

Atherosclerosis End-User Outlook

• Hospitals


• Specialty Clinics


• Homecare


• Others

Atherosclerosis Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America